600833.SH
Shanghai No. 1 Pharmacy Co. Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 10.46
−1.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1B | 2.1B | 1.9B | 1.8B | 2.7B |
| Cost of Revenue | 1.8B | 1.8B | 1.6B | 1.5B | 2.1B |
| Gross Profit | 327.3M | 341.5M | 318.5M | 347.6M | 545.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 72.8M | 71.6M | 67.8M | 77.9M | 84.8M |
| Selling & Marketing Expense | 260.5M | 269.1M | 252.3M | 239.3M | 223.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 331.2M | 339.4M | 311.9M | 320.0M | 318.9M |
| Cost and Expenses | 2.1B | 2.1B | 1.9B | 1.8B | 2.4B |
| Operating Income (EBIT) | 99.2M | 74.7M | 208.1M | 99.0M | 190.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 100.6M | 76.0M | 216.3M | 117.5M | 190.5M |
| Income Tax Expense | 23.2M | 17.5M | 52.7M | 28.2M | 47.0M |
| Bottom Line | |||||
| Net Income | 76.3M | 57.7M | 163.1M | 89.3M | 143.6M |
| Earnings from Cont. Ops | 77.4M | 58.5M | 163.6M | 89.3M | 143.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 76.3M | 57.7M | 163.1M | 89.3M | 143.6M |
| Per Share | |||||
| Basic EPS | CN¥0.34 | CN¥0.26 | CN¥0.73 | CN¥0.40 | CN¥0.64 |
| Diluted EPS | CN¥0.34 | CN¥0.26 | CN¥0.73 | CN¥0.40 | CN¥0.64 |
| Revenue Per Share | CN¥9.46 | CN¥9.59 | CN¥8.57 | CN¥8.15 | CN¥11.84 |
| Shares | |||||
| Basic Shares Outstanding | 223.0M | 222.1M | 223.4M | 223.2M | 224.3M |
| Diluted Shares Outstanding | 223.0M | 222.1M | 223.4M | 223.2M | 224.3M |
| Profitability Metrics | |||||
| EBITDA | — | 90.6M | 221.9M | 112.1M | 203.1M |
| D&A | — | 15.9M | 13.9M | 13.1M | 12.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026